Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DEB-TACE plus Lenvatinib, Sorafenib, or PD-1 Inhibitor in Unresectable HCC
NCT04229355Phase 3Unknown
- Sponsor
- Guangxi Medical University
- Start
- Feb 2021
- Primary completion
- Dec 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of lenvatinib in hepatocellular carcinoma (HCC), sponsored by Guangxi Medical University. Status: unknown.
02
Drugs
lenvatinib
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT04229355.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04229355.